Publicacións en colaboración con investigadores/as de Aarhus University (79)

2024

  1. Association between type 2 diabetes and depressive symptoms after a 1-year follow-up in an older adult Mediterranean population

    Journal of Endocrinological Investigation

  2. Cholesterol lowering depletes atherosclerotic lesions of smooth muscle cell-derived fibromyocytes and chondromyocytes

    Nature Cardiovascular Research, Vol. 3, Núm. 2, pp. 203-220

  3. Correction: Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report (International Journal of Mental Health and Addiction, (2023), 10.1007/s11469-023-01213-9)

    International Journal of Mental Health and Addiction

  4. Erratum: Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome medicine (2023) 15 1 (22))

    Genome medicine

  5. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

    The Journal of experimental medicine, Vol. 221, Núm. 2

  6. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

    Seminars in Arthritis and Rheumatism, Vol. 65

2023

  1. A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

    OncoImmunology, Vol. 12, Núm. 1

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  4. Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2

    Advanced Science, Vol. 10, Núm. 34

  5. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

    The Lancet Regional Health - Europe, Vol. 33

  6. European survey on the use of patient contact shielding during radiological examinations

    Insights into Imaging, Vol. 14, Núm. 1

  7. Imaging of CO2 and Dissolved Inorganic Carbon via Electrochemical Acidification-Optode Tandem

    ACS Sensors, Vol. 8, Núm. 7, pp. 2843-2851

  8. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

  9. Novel Loss-of-Function KCNA5 Variants in Pulmonary Arterial Hypertension

    American Journal of Respiratory Cell and Molecular Biology, Vol. 69, Núm. 2, pp. 147-158

  10. Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report

    International Journal of Mental Health and Addiction

  11. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities

    PLoS pathogens, Vol. 19, Núm. 1, pp. e1011063

  12. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

    Genome Medicine, Vol. 15, Núm. 1

  13. Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: Results from the EuroSpA Research Collaboration Network

    RMD Open, Vol. 9, Núm. 4

  14. Topography of immune cell infiltration in different stages of coronary atherosclerosis revealed by multiplex immunohistochemistry

    IJC Heart and Vasculature, Vol. 44